Stada Pharmaceuticals Inc., alongside with PE funds such as BC Partners, CVC Capital Partners, PAI Partners are bidding for UPSA Sas, the deal value is near $1.15 billion.

Backed by PE Fund, Stada Pharmaceuticals, worlwide developer of pharmaceuticals products, bidds for UPSA Sas, Bristol-Myers Squibb French business, which is engaged in painkillers manufacturing, alongside with a number of PE funds such as: BC Partners, private equity firm specializing in investments in acquisitions and growth capital, CVC Capital Partners, private equity firm specializing in middle market and mature, PAI Partners, private equity firm specializing in leveraged buyouts. The potential deal value is $1,15 billion.